None listed
Conditions
Brief summary
To investigate the ability of tcDCS to prevent or attenuate cybersickness experienced in Virtual Reality (VR). Outcomes include incidence of cybersickness, the severity of cybersickness, changes in cortical activation of sites under EEG channels compared to other channels.
Interventions
There will be a 2 minute baseline seated rest recording of electroencephalogram (EEG) and a custom algorithm run straight after to predict cybersickness based on the EEG data. Afterwards if a positive prediction for cybersickness was observed, there will be immediate transition to application of high definition transcranial direct current stimulation applied at Cz for anodal, cathodal, anodal and sham, with surrounding return electrodes at Fc1, Fc2, Cp1, Cp2 (10-10 electrode system). Delivered a
There will be a 2 minute baseline seated rest recording of electroencephalogram (EEG) and a custom algorithm run straight after to predict cybersickness based on the EEG data. Afterwards if a positive prediction for cybersickness was observed, there will be immediate transition to application of high definition transcranial direct current stimulation applied at Cz for anodal, cathodal, anodal and sham, with surrounding return electrodes at Fc1, Fc2, Cp1, Cp2 (10-10 electrode system). Delivered at a safe 1.5mA for 5 minutes plus 30 second ramp up/down, once per day per stimulation type, for a total of 3 sessions, at least 24 hours apart as a washout period, which can be consecutive or non consecutive. Using a Neuroelectrics starstim32 hybrid stimulator, NG Pistim electrodes (p cm2Ag/AgCl/gel electrode, radius 1cm), stimulation delivered by experiment conductor. Sham only includes 30 second ramp up/down. After each 5 minute stimulation + 1 minute for the ramp up and down there will be a 10 minute VR immersion period, and a 2 minute recovery period. The entire duration of the session is anticipated to run for about 20 minutes including baseline recordings, stimulation, VR immersion, and recovery period . The intervention is given at Hercus building, 60 Hanover Street, Central Dunedin, Dunedin 9016.
Sponsors
University of Otago
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
Without prior neurological, cardiovascular, gastrointestinal disease, and not on regular medication or drugs. Inclusion was further restricted only to those susceptible to cybersickness (CS). A score of 10 or above on the visually induced motion sickness questionnaire (VIMSSQ).
Exclusion criteria
implanted devices, head implants containing metal (outside of mouth), head wound, skin condition on scalp, previous adverse reactions to tDCS, pregnancy.
Outcome results
None listed